KR100719273B1 - 피부 패치 시트 및 그것을 위한 베이스 시트의 제조 방법 - Google Patents
피부 패치 시트 및 그것을 위한 베이스 시트의 제조 방법 Download PDFInfo
- Publication number
- KR100719273B1 KR100719273B1 KR1019997005815A KR19997005815A KR100719273B1 KR 100719273 B1 KR100719273 B1 KR 100719273B1 KR 1019997005815 A KR1019997005815 A KR 1019997005815A KR 19997005815 A KR19997005815 A KR 19997005815A KR 100719273 B1 KR100719273 B1 KR 100719273B1
- Authority
- KR
- South Korea
- Prior art keywords
- styrene
- film
- weight
- composite
- polyvinyl chloride
- Prior art date
Links
Images
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B32—LAYERED PRODUCTS
- B32B—LAYERED PRODUCTS, i.e. PRODUCTS BUILT-UP OF STRATA OF FLAT OR NON-FLAT, e.g. CELLULAR OR HONEYCOMB, FORM
- B32B27/00—Layered products comprising a layer of synthetic resin
- B32B27/06—Layered products comprising a layer of synthetic resin as the main or only constituent of a layer, which is next to another layer of the same or of a different material
- B32B27/08—Layered products comprising a layer of synthetic resin as the main or only constituent of a layer, which is next to another layer of the same or of a different material of synthetic resin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B32—LAYERED PRODUCTS
- B32B—LAYERED PRODUCTS, i.e. PRODUCTS BUILT-UP OF STRATA OF FLAT OR NON-FLAT, e.g. CELLULAR OR HONEYCOMB, FORM
- B32B27/00—Layered products comprising a layer of synthetic resin
- B32B27/30—Layered products comprising a layer of synthetic resin comprising vinyl (co)polymers; comprising acrylic (co)polymers
- B32B27/302—Layered products comprising a layer of synthetic resin comprising vinyl (co)polymers; comprising acrylic (co)polymers comprising aromatic vinyl (co)polymers, e.g. styrenic (co)polymers
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B32—LAYERED PRODUCTS
- B32B—LAYERED PRODUCTS, i.e. PRODUCTS BUILT-UP OF STRATA OF FLAT OR NON-FLAT, e.g. CELLULAR OR HONEYCOMB, FORM
- B32B27/00—Layered products comprising a layer of synthetic resin
- B32B27/30—Layered products comprising a layer of synthetic resin comprising vinyl (co)polymers; comprising acrylic (co)polymers
- B32B27/304—Layered products comprising a layer of synthetic resin comprising vinyl (co)polymers; comprising acrylic (co)polymers comprising vinyl halide (co)polymers, e.g. PVC, PVDC, PVF, PVDF
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B32—LAYERED PRODUCTS
- B32B—LAYERED PRODUCTS, i.e. PRODUCTS BUILT-UP OF STRATA OF FLAT OR NON-FLAT, e.g. CELLULAR OR HONEYCOMB, FORM
- B32B27/00—Layered products comprising a layer of synthetic resin
- B32B27/32—Layered products comprising a layer of synthetic resin comprising polyolefins
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B32—LAYERED PRODUCTS
- B32B—LAYERED PRODUCTS, i.e. PRODUCTS BUILT-UP OF STRATA OF FLAT OR NON-FLAT, e.g. CELLULAR OR HONEYCOMB, FORM
- B32B27/00—Layered products comprising a layer of synthetic resin
- B32B27/36—Layered products comprising a layer of synthetic resin comprising polyesters
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B32—LAYERED PRODUCTS
- B32B—LAYERED PRODUCTS, i.e. PRODUCTS BUILT-UP OF STRATA OF FLAT OR NON-FLAT, e.g. CELLULAR OR HONEYCOMB, FORM
- B32B27/00—Layered products comprising a layer of synthetic resin
- B32B27/40—Layered products comprising a layer of synthetic resin comprising polyurethanes
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B32—LAYERED PRODUCTS
- B32B—LAYERED PRODUCTS, i.e. PRODUCTS BUILT-UP OF STRATA OF FLAT OR NON-FLAT, e.g. CELLULAR OR HONEYCOMB, FORM
- B32B7/00—Layered products characterised by the relation between layers; Layered products characterised by the relative orientation of features between layers, or by the relative values of a measurable parameter between layers, i.e. products comprising layers having different physical, chemical or physicochemical properties; Layered products characterised by the interconnection of layers
- B32B7/04—Interconnection of layers
- B32B7/12—Interconnection of layers using interposed adhesives or interposed materials with bonding properties
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B32—LAYERED PRODUCTS
- B32B—LAYERED PRODUCTS, i.e. PRODUCTS BUILT-UP OF STRATA OF FLAT OR NON-FLAT, e.g. CELLULAR OR HONEYCOMB, FORM
- B32B2327/00—Polyvinylhalogenides
- B32B2327/06—PVC, i.e. polyvinylchloride
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B32—LAYERED PRODUCTS
- B32B—LAYERED PRODUCTS, i.e. PRODUCTS BUILT-UP OF STRATA OF FLAT OR NON-FLAT, e.g. CELLULAR OR HONEYCOMB, FORM
- B32B2367/00—Polyesters, e.g. PET, i.e. polyethylene terephthalate
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B32—LAYERED PRODUCTS
- B32B—LAYERED PRODUCTS, i.e. PRODUCTS BUILT-UP OF STRATA OF FLAT OR NON-FLAT, e.g. CELLULAR OR HONEYCOMB, FORM
- B32B2375/00—Polyureas; Polyurethanes
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B32—LAYERED PRODUCTS
- B32B—LAYERED PRODUCTS, i.e. PRODUCTS BUILT-UP OF STRATA OF FLAT OR NON-FLAT, e.g. CELLULAR OR HONEYCOMB, FORM
- B32B2556/00—Patches, e.g. medical patches, repair patches
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Preparation (AREA)
- Laminated Bodies (AREA)
- Materials For Medical Uses (AREA)
- Cosmetics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
실 시 예 | 비교예 | ||||||||
1 | 2 | 3 | 4 | 5 | 1 | 2 | |||
복합필름배합 (중량부) | PVC-폴리우레탄복합체 | 쇼어A경도 90 | 100 | ||||||
쇼어A경도 80 | 100 | ||||||||
쇼어A경도 55 | 100 | 100 | 100 | 100 | 100 | ||||
SEBS 1) | 2 | 8 | 5 | 5 | 2 | 1 | 15 | ||
안정제 2) | 2 | 2 | 2 | 2 | 2 | 2 | 2 | ||
하석섬장암 3) | 10 | ||||||||
평가 | 겔화성(롤 가공성) | A | B | B | A | A | A | C | |
복합 필름의 전개성 | B | A | A | A | AA | C | A | ||
베이스 시트의 층간 접착력 (g/19mm) | 420 | 730 | 510 | 550 | 420 | 390 | 890 | ||
접착제 잔류물 | A | A | A | A | A | A | A | ||
피부와의 적합성 | A | A | A | A | A | A | A |
Claims (15)
- 폴리염화비닐-폴리우레탄 복합체 100 중량부와 스티렌-에틸렌-부틸렌-스티렌 공중합체 2 내지 10 중량부의 배합물로 실질적으로 구성된 수지조성물로 제조된 복합필름, 이 복합필름 한쪽 면상의 폴리우레탄 접착제층, 및 이 폴리우레탄 접착제층에 의하여 이 복합필름 한쪽 면에 접착되고, 또 10㎛ 이하의 두께를 갖는 폴리에틸렌 테레프탈레이트 필름을 포함하는 기재 시트; 상기 폴리에틸렌 테레프탈레이트 필름 표면상에 형성되고, 포화 폴리에스테르 수지를 포함하는 프라이머층; 및 상기 프라이머층에 적층된 약제를 함유하며 스티렌-디엔-스티렌블록공중합체를 포함하는 접착제층을 함유하는 피부패치시트.
- 제1항에 있어서, 폴리우레탄 접착제 층이 두께 1.0 내지 8.0 ㎛의 층인 것을 특징으로 하는 피부 패치 시트.
- 제1항에 있어서, 상기 수지조성물이 폴리염화비닐-폴리우레탄 복합체 100 중량부, 스티렌-에틸렌-부틸렌-스티렌 공중합체 2 내지 10 중량부와 평균입도 3-10㎛의 무기 미립자 5 내지 30 중량부의 배합물로 실질적으로 구성된 것을 특징으로 하는 피부 패치 시트.
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 폴리염화비닐-폴리우레탄 복합체 100 중량부와 스티렌-에틸렌-부틸렌-스티렌 공중합체 2 내지 10 중량부의 배합물로 실질적으로 구성된 수지 조성물을 제조하는 단계, 이 수지 조성물을 캘린더 가공에 의해 복합 필름으로 성형하는 단계; 폴리우레탄 접착제 층을 사용하여 이 복합 필름의 한쪽 면에 10㎛ 이하의 두께를 갖는 폴리에틸렌 테레프탈레이트 필름을 접착시켜서 기재 시트를 형성하는 단계; 이 폴리에틸렌 테레프탈레이트 필름의 외측 표면에 포화 폴리에스테르 수지를 포함하는 프라이머 층을 형성하는 단계; 및 이어 이 프라이머 층에 약제를 함유하며 스티렌-디엔-스티렌 블록공중합체를 포함하는 접착제층을 형성하는 단계를 포함하는 피부 패치 시트의 제조 방법.
- 제11항에 있어서, 상기 수지조성물이 폴리염화비닐-폴리우레탄 복합체 100 중량부, 스티렌-에틸렌-부틸렌-스티렌 공중합체 2 내지 10 중량부와 평균입도 3-10㎛의 무기 미립자 5 내지 30 중량부의 배합물로 실질적으로 구성된 것을 특징으로 하는 피부 패치 시트의 제조 방법.
- 제12항에 있어서, 무기 미립자가 하석섬장암(nepheline syenite)인 것을 특징으로 하는 피부 패치 시트의 제조 방법.
- 제11항에 있어서, 폴리우레탄 접착제 층이 두께 1.0 내지 8.0 ㎛의 층인 것을 특징으로 하는 피부 패치 시트의 제조 방법.
- 제3항에 있어서, 무기미립자가 하석섬장암(nepheline syenite)인 것을 특징으로 하는 피부 패치 시트.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP97-295103 | 1997-10-28 | ||
JP29510397 | 1997-10-28 | ||
PCT/JP1998/004850 WO1999021537A1 (fr) | 1997-10-28 | 1998-10-26 | Feuille de timbre cutane et procede de production d'une feuille de base pour timbre |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20000069728A KR20000069728A (ko) | 2000-11-25 |
KR100719273B1 true KR100719273B1 (ko) | 2007-05-18 |
Family
ID=17816342
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1019997005815A KR100719273B1 (ko) | 1997-10-28 | 1998-10-26 | 피부 패치 시트 및 그것을 위한 베이스 시트의 제조 방법 |
Country Status (11)
Country | Link |
---|---|
US (1) | US6267983B1 (ko) |
EP (1) | EP0968711B9 (ko) |
JP (1) | JP4395200B2 (ko) |
KR (1) | KR100719273B1 (ko) |
CN (1) | CN1152673C (ko) |
AT (1) | ATE387192T1 (ko) |
AU (1) | AU730850B2 (ko) |
CA (1) | CA2275539A1 (ko) |
DE (1) | DE69839179T2 (ko) |
TW (1) | TW518228B (ko) |
WO (1) | WO1999021537A1 (ko) |
Families Citing this family (131)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7166719B2 (en) | 2002-06-27 | 2007-01-23 | Health Research, Inc. | Fluorinated photosensitizers related to chlorins and bacteriochlorins for photodynamic therapy |
US7897140B2 (en) | 1999-12-23 | 2011-03-01 | Health Research, Inc. | Multi DTPA conjugated tetrapyrollic compounds for phototherapeutic contrast agents |
US7921999B1 (en) * | 2001-12-20 | 2011-04-12 | Watson Laboratories, Inc. | Peelable pouch for transdermal patch and method for packaging |
MY138871A (en) * | 2003-04-22 | 2009-08-28 | Sumitomo Chemical Co | Insect pest control heat vaporizing material |
EP1628666B1 (en) * | 2003-05-14 | 2015-09-23 | NeuroGenetic Pharmaceuticals, Inc. | Compouds and uses thereof in modulating amyloid beta |
WO2005090370A1 (en) | 2004-02-05 | 2005-09-29 | The Regents Of The University Of California | Pharmacologically active agents containing esterified phosphonates and methods for use thereof |
WO2005112913A1 (en) | 2004-05-20 | 2005-12-01 | The Scripps Research Institute | Transthyretin stabilization |
EP1765332A2 (en) * | 2004-06-17 | 2007-03-28 | Cengent Therapeutics, Inc. | Trisubstituted nitrogen modulators of tyrosine phosphatases |
US20060135483A1 (en) * | 2004-07-09 | 2006-06-22 | Cheruvallath Zacharia S | Oxygen/nitrogen heterocycle inhibitors of tyrosine phosphatases |
WO2006028970A1 (en) | 2004-09-02 | 2006-03-16 | Cengent Therapeutics, Inc. | Derivatives of thiazole and thiadiazole inhibitors of tyrosine phosphatases |
NZ584773A (en) | 2004-09-17 | 2012-07-27 | Whitehead Biomedical Inst | Compounds, Compositions and Methods of Inhibiting Alpha-Synuclein Toxicity |
JP4804007B2 (ja) | 2005-01-13 | 2011-10-26 | 日東電工株式会社 | 粘着製品 |
WO2006130217A2 (en) * | 2005-04-01 | 2006-12-07 | The Regents Of The University Of California | Substituted phosphate esters of nucleoside phosphonates |
US8222257B2 (en) | 2005-04-01 | 2012-07-17 | The Regents Of The University Of California | Phosphono-pent-2-en-1-yl nucleosides and analogs |
WO2007002109A2 (en) * | 2005-06-20 | 2007-01-04 | The Regents Of The University Of California | Multidentate pyrone-derived chelators for medicinal imaging and chelation |
US20080058282A1 (en) | 2005-08-30 | 2008-03-06 | Fallon Joan M | Use of lactulose in the treatment of autism |
US8492428B2 (en) * | 2005-09-20 | 2013-07-23 | Mayo Foundation For Medical Education And Research | Small-molecule botulinum toxin inhibitors |
JP5036270B2 (ja) * | 2005-12-02 | 2012-09-26 | 日東電工株式会社 | 加熱剥離型粘着シートおよびこの加熱剥離型粘着シートを用いた半導体チップの製造方法 |
EP2007373A4 (en) * | 2006-03-29 | 2012-12-19 | Foldrx Pharmaceuticals Inc | INHIBITION OF ALPHA SYNUCLEINE TOXICITY |
ES2439994T3 (es) | 2006-08-28 | 2014-01-27 | Kyowa Hakko Kirin Co., Ltd. | Anticuerpos antagonistas monoclonales humanos específicos de LIGHT humano |
US20090264421A1 (en) * | 2007-10-05 | 2009-10-22 | Bible Keith C | Methods and Compositions for Treating Cancer |
US8426587B2 (en) * | 2007-11-21 | 2013-04-23 | Pharmaxis Ltd. | Haloallylamine inhibitors of SSAO/VAP-1 and uses therefor |
US8658163B2 (en) | 2008-03-13 | 2014-02-25 | Curemark Llc | Compositions and use thereof for treating symptoms of preeclampsia |
US8084025B2 (en) | 2008-04-18 | 2011-12-27 | Curemark Llc | Method for the treatment of the symptoms of drug and alcohol addiction |
ES2732453T3 (es) | 2008-07-01 | 2019-11-22 | Curemark Llc | Métodos y composiciones para el tratamiento de síntomas de trastornos neurológicos y de salud mental |
AU2010203709B2 (en) | 2009-01-06 | 2014-05-22 | Galenagen, Llc | Compositions and methods for the treatment or prevention of Staphylococcus Aureus infections and for the Eradication or reduction of Staphylococcus Aureus on surfaces |
WO2010080835A1 (en) | 2009-01-06 | 2010-07-15 | Curemark Llc | Compositions and methods for the treatment or the prevention oral infections by e. coli |
US9056050B2 (en) | 2009-04-13 | 2015-06-16 | Curemark Llc | Enzyme delivery systems and methods of preparation and use |
US8920392B2 (en) * | 2009-05-05 | 2014-12-30 | Watson Laboratories, Inc. | Method for treating overactive bladders and a device for storage and administration of topical oxybutynin compositions |
US8404728B2 (en) | 2009-07-30 | 2013-03-26 | Mayo Foundation For Medical Education And Research | Small-molecule botulinum toxin inhibitors |
US8871460B2 (en) | 2009-11-09 | 2014-10-28 | Neurogenetic Pharmaceuticals, Inc. | Gamma-secretase modulatory compounds, methods for identifying same, and uses therefor |
US20110301235A1 (en) | 2009-12-02 | 2011-12-08 | Alquest Therapeutics, Inc. | Organoselenium compounds and uses thereof |
SG181896A1 (en) * | 2009-12-23 | 2012-07-30 | Map Pharmaceuticals Inc | Novel ergoline analogs |
JP6069661B2 (ja) | 2010-06-24 | 2017-02-01 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 種々のアミロイドβペプチドアロフォームレベルの調節における組成物及びその使用 |
DK2701733T3 (da) | 2011-04-21 | 2019-05-27 | Curemark Llc | Forbindelser til behandling af neuropsykiatriske forstyrrelser |
US8604035B2 (en) | 2011-06-23 | 2013-12-10 | Map Pharmaceuticals, Inc. | Fluoroergoline analogs |
WO2013037482A1 (en) | 2011-09-15 | 2013-03-21 | Phenex Pharmaceuticals Ag | Farnesoid x receptor agonists for cancer treatment and prevention |
SG11201403434YA (en) | 2011-12-19 | 2014-09-26 | Map Pharmaceuticals Inc | Novel iso-ergoline derivatives |
EP2793583A4 (en) | 2011-12-21 | 2015-08-12 | Map Pharmaceuticals Inc | NOVEL NEUROMODULATORY CONNECTIONS |
SG10201707020TA (en) | 2012-05-02 | 2017-10-30 | Boehringer Ingelheim Int | Substituted 3-haloallylamine inhibitors of ssao and uses thereof |
SG11201407322QA (en) | 2012-05-23 | 2014-12-30 | Cellix Bio Private Ltd | Compositions and methods for the treatment of multiple sclerosis |
CA2873096A1 (en) | 2012-05-23 | 2013-11-28 | Cellixbio Private Limited | Compositions and methods for the treatment of inflammatory bowel disease |
US10350278B2 (en) | 2012-05-30 | 2019-07-16 | Curemark, Llc | Methods of treating Celiac disease |
WO2013187965A1 (en) | 2012-06-14 | 2013-12-19 | Mayo Foundation For Medical Education And Research | Pyrazole derivatives as inhibitors of stat3 |
US9012640B2 (en) | 2012-06-22 | 2015-04-21 | Map Pharmaceuticals, Inc. | Cabergoline derivatives |
US9074186B2 (en) | 2012-08-15 | 2015-07-07 | Boston Medical Center Corporation | Production of red blood cells and platelets from stem cells |
WO2014100354A1 (en) | 2012-12-21 | 2014-06-26 | Map Pharmaceuticals, Inc. | Novel methysergide derivatives |
US9169214B2 (en) | 2012-12-21 | 2015-10-27 | The Board Of Trustees Of The Leland Stanford Junior University | Compounds and compositions that bind and stabilize transthyretin and their use for inhibiting transthyretin amyloidosis and protein-protein interactions |
EP2968296B1 (en) | 2013-03-12 | 2020-09-02 | The Regents of the University of California | Gamma-secretase modulators |
SG10201708143QA (en) | 2013-06-06 | 2017-11-29 | Pierre Fabre Médicament | Anti-c10orf54 antibodies and uses thereof |
GB201403775D0 (en) | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
CN108064242B (zh) | 2014-05-28 | 2022-10-21 | 阿吉纳斯公司 | 抗gitr抗体和其使用方法 |
WO2016025129A1 (en) | 2014-08-14 | 2016-02-18 | Alhamadsheh Mamoun M | Conjugation of pharmaceutically active agents with transthyretin ligands through adjustable linkers to increase serum half-life |
WO2016046835A1 (en) | 2014-09-26 | 2016-03-31 | Cellix Bio Private Limited | Compositions and methods for the treatment of epilepsy and neurological disorders |
CN107207403A (zh) | 2014-09-29 | 2017-09-26 | 塞尔利克斯生物私人有限公司 | 用于治疗多发性硬化的组合物和方法 |
SG11201703369WA (en) | 2014-10-27 | 2017-05-30 | Cellix Bio Private Ltd | Three component salts of fumaric acid monomethyl ester with piperazine or ethylene diamine for the treatment of multiple sclerosis |
WO2016067297A1 (en) | 2014-10-27 | 2016-05-06 | Cellix Bio Private Limited | Salts of valproic acid with piperazine, ethylenediamine, lysine and/or eicosapentaenoic ecid (epa) amine derivatives for the treatment of epilepsy |
BR112017009010A2 (pt) | 2014-10-31 | 2017-12-26 | Massachusetts Gen Hospital | moduladores potentes de gama-secretase |
EP3226855A1 (en) | 2014-12-01 | 2017-10-11 | Cellix Bio Private Limited | Compositions and methods for the treatment of multiple sclerosis |
PL3333191T3 (pl) | 2014-12-11 | 2021-05-04 | Pierre Fabre Médicament | Przeciwciała przeciwko c10orf54 i ich zastosowania |
WO2016106221A1 (en) | 2014-12-22 | 2016-06-30 | The Rockefeller University | Anti-mertk agonistic antibodies and uses thereof |
US9676776B2 (en) | 2015-01-20 | 2017-06-13 | Xoc Pharmaceuticals, Inc. | Isoergoline compounds and uses thereof |
EP3253753A4 (en) | 2015-01-20 | 2018-06-27 | Xoc Pharmaceuticals, Inc | Ergoline compounds and uses thereof |
SG10201906474QA (en) | 2015-02-09 | 2019-09-27 | Cellix Bio Private Ltd | Compositions and methods for the treatment of mucositis |
FI3265123T3 (fi) | 2015-03-03 | 2023-01-31 | Vasta-aineita, käyttöjä & menetelmiä | |
WO2016176617A2 (en) | 2015-04-29 | 2016-11-03 | New York University | Method for treating high-grade gliomas |
PT3303394T (pt) | 2015-05-29 | 2020-07-01 | Ludwig Inst For Cancer Res Ltd | Anticorpos anti-ctla-4 e métodos de uso dos mesmos |
KR20220131277A (ko) | 2015-09-01 | 2022-09-27 | 아게누스 인코포레이티드 | 항-pd-1 항체 및 이를 이용하는 방법 |
US10112924B2 (en) | 2015-12-02 | 2018-10-30 | Astraea Therapeutics, Inc. | Piperdinyl nociceptin receptor compounds |
US10960013B2 (en) | 2016-03-04 | 2021-03-30 | East Carolina University | J-series prostaglandin-ethanolamides as novel therapeutics for skin and/or oral disorders |
EP3426352A4 (en) | 2016-03-08 | 2019-11-13 | Los Gatos Pharmaceuticals, Inc. | CAMPTOTHECIN DERIVATIVES AND USES THEREOF |
EP3426301A4 (en) | 2016-03-08 | 2019-11-06 | Los Gatos Pharmaceuticals, Inc. | VERBUNDNANOPARTICLES AND USES THEREOF |
US10047077B2 (en) | 2016-04-13 | 2018-08-14 | Skyline Antiinfectives, Inc. | Deuterated O-sulfated beta-lactam hydroxamic acids and deuterated N-sulfated beta-lactams |
WO2017194789A1 (en) | 2016-05-13 | 2017-11-16 | Institut Pasteur | Inhibition of beta-2 nicotinic acetylcholine receptors to treat alzheimer's disease pathology |
MA45123A (fr) | 2016-05-27 | 2019-04-10 | Agenus Inc | Anticorps anti-tim-3 et leurs méthodes d'utilisation |
AU2017292184A1 (en) | 2016-07-08 | 2019-02-07 | Staten Biotechnology B.V. | Anti-Apoc3 antibodies and methods of use thereof |
MX2019001360A (es) | 2016-08-11 | 2019-06-03 | Cellix Bio Private Ltd | Composiciones y metodos para el tratamiento de sindrome de intestino irritable. |
WO2018035281A1 (en) | 2016-08-17 | 2018-02-22 | North Carolina State University | Northern-southern route to synthesis of bacteriochlorins |
DK3522873T3 (da) | 2016-10-04 | 2022-06-20 | Cellix Bio Private Ltd | Sammensætninger og fremgangsmåder til behandlingen af xerostomi |
CN110023337B (zh) | 2016-10-11 | 2024-01-05 | 艾吉纳斯公司 | 抗lag-3抗体及其使用方法 |
US11779604B2 (en) | 2016-11-03 | 2023-10-10 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses and methods |
US11332521B2 (en) | 2016-11-07 | 2022-05-17 | Neuracle Science Co., Ltd. | Anti-family with sequence similarity 19, member A5 antibodies and method of use thereof |
WO2018089692A1 (en) | 2016-11-09 | 2018-05-17 | Phloronol, Inc. | Eckol derivatives, methods of synthesis and uses thereof |
WO2018102252A1 (en) | 2016-11-30 | 2018-06-07 | North Carolina State University | Methods for making bacteriochlorin macrocycles comprising an annulated isocyclic ring and related compounds |
AU2017373944B2 (en) | 2016-12-07 | 2022-02-03 | Agenus Inc. | Anti-CTLA-4 antibodies and methods of use thereof |
CA3046082A1 (en) | 2016-12-07 | 2018-06-14 | Agenus Inc. | Antibodies and methods of use thereof |
WO2018115984A1 (en) | 2016-12-19 | 2018-06-28 | Cellix Bio Private Limited | Compositions and methods for the treatment of inflammation |
MA47511A (fr) | 2017-02-17 | 2019-12-25 | Eidos Therapeutics Inc | Procédés de préparation d'ag-10, de ses intermédiaires et de sels correspondants |
AU2018220515B2 (en) | 2017-02-17 | 2022-06-30 | DayLife LLC | Universal antivenom |
BR112019017241A2 (pt) | 2017-04-13 | 2020-04-14 | Agenus Inc | anticorpos anti-cd137 e métodos de uso dos mesmos |
JP2020517242A (ja) | 2017-04-21 | 2020-06-18 | スターテン・バイオテクノロジー・ベー・フェー | 抗ApoC3抗体およびその使用方法 |
EP3618863B1 (en) | 2017-05-01 | 2023-07-26 | Agenus Inc. | Anti-tigit antibodies and methods of use thereof |
AU2018275873A1 (en) | 2017-06-01 | 2019-12-19 | Xoc Pharmaceuticals, Inc. | Ergoline derivatives for use in medicine |
EP3645029B1 (en) | 2017-06-26 | 2023-01-18 | Institut Pasteur | Treatments to eliminate hiv reservoirs and reduce viral load |
KR102340352B1 (ko) | 2017-06-27 | 2021-12-21 | 주식회사 뉴라클사이언스 | 섬유증의 치료를 위한 항-fam19a5 항체의 용도 |
KR102454460B1 (ko) | 2017-06-27 | 2022-10-17 | 주식회사 뉴라클사이언스 | 암 치료를 위한 항-fam19a5 항체의 용도 |
BR112019027729A2 (pt) | 2017-06-27 | 2020-08-18 | Neuracle Science Co., Ltd | anticorpos anti-fam19a5 e seus usos |
CN110972463B (zh) | 2017-06-27 | 2024-05-28 | 纽洛可科学有限公司 | 抗序列相似家族19成员a5抗体在治疗青光眼中的用途 |
AU2018306718A1 (en) | 2017-07-27 | 2020-02-20 | Allergan, Inc. | Prostacyclin receptor agonists for reduction of body fat |
US11571401B2 (en) | 2017-09-01 | 2023-02-07 | East Carolina University | Compounds, compositions, kits, and methods for activating immune cells and/or an immune system response |
CN111315772A (zh) | 2017-10-31 | 2020-06-19 | 斯塔顿生物技术有限公司 | 抗apoc3抗体及其使用方法 |
JP7038437B2 (ja) | 2017-11-17 | 2022-03-18 | セリックス バイオ プライヴェート リミテッド | 眼障害及び皮膚疾患の処置のための化合物、組成物、及び方法 |
CN111372576A (zh) | 2017-11-17 | 2020-07-03 | 塞尔利克斯生物私人有限公司 | 用于治疗眼部病症的组合物和方法 |
KR20200135996A (ko) | 2018-03-23 | 2020-12-04 | 에이도스 테라퓨틱스, 인코포레이티드 | Ag10을 사용하여 ttr 아밀로이드증을 치료하는 방법 |
KR20200118913A (ko) | 2018-04-24 | 2020-10-16 | 주식회사 뉴라클사이언스 | 신경병성 통증의 치료를 위한 서열 유사성 19, 멤버 a5 항체를 갖는 항-패밀리의 용도 |
KR20240056644A (ko) | 2018-05-10 | 2024-04-30 | 주식회사 뉴라클사이언스 | 서열 유사성 19, 멤버 a5 항체를 갖는 항-패밀리 및 그의 사용 방법 |
CN112740043A (zh) | 2018-07-20 | 2021-04-30 | 皮埃尔法布雷医药公司 | Vista受体 |
WO2020037189A1 (en) | 2018-08-17 | 2020-02-20 | Eidos Therapeutics, Inc. | Formulations of ag10 |
KR20210070300A (ko) | 2018-10-03 | 2021-06-14 | 스태튼 바이오테크놀로지 비.브이. | 사람 및 시노몰구스 ApoC3에 대해 특이적인 항체 및 이의 사용 방법 |
US20220008515A1 (en) | 2018-11-16 | 2022-01-13 | Neoimmunetech, Inc. | Method of treating a tumor with a combination of il-7 protein and an immune checkpoint inhibitor |
WO2020128033A1 (en) | 2018-12-20 | 2020-06-25 | Institut Pasteur | Cellular metabolism of hiv-1 reservoir seeding in cd4+ t cells |
EP3921038A1 (en) | 2019-02-06 | 2021-12-15 | Dice Alpha, Inc. | Il-17a modulators and uses thereof |
EP4378958A2 (en) | 2019-02-26 | 2024-06-05 | Inspirna, Inc. | High-affinity anti-mertk antibodies and uses thereof |
CA3138403A1 (en) | 2019-05-20 | 2020-11-26 | Christopher J. MACNEVIN | Narrow emission dyes, compositions comprising same, and methods for making and using same |
WO2021042019A1 (en) | 2019-08-30 | 2021-03-04 | Agenus Inc. | Anti-cd96 antibodies and methods of use thereof |
JP2022547617A (ja) | 2019-09-16 | 2022-11-14 | ダイス アルファ,インク. | Il-17aモジュレーターおよびその使用 |
IL294663A (en) | 2020-01-13 | 2022-09-01 | Neoimmunetech Inc | A method for tumor treatment with a combination of il-7 protein and a bispecific antibody |
EP4100045A1 (en) | 2020-02-05 | 2022-12-14 | Washington University | Method of treating a solid tumor with a combination of an il-7 protein and car-bearing immune cells |
US11541009B2 (en) | 2020-09-10 | 2023-01-03 | Curemark, Llc | Methods of prophylaxis of coronavirus infection and treatment of coronaviruses |
WO2022093718A1 (en) | 2020-10-26 | 2022-05-05 | Neoimmunetech, Inc. | Methods of inducing stem cell mobilization |
WO2022094475A1 (en) | 2020-11-02 | 2022-05-05 | Neoimmunetech, Inc. | Use of interleukin-7 for the treatment of coronavirus |
JP2023549112A (ja) | 2020-11-05 | 2023-11-22 | ネオイミューンテック, インコーポレイテッド | Il-7タンパク質とヌクレオチドワクチンの組み合わせで腫瘍を治療する方法 |
IL305752A (en) | 2021-03-10 | 2023-11-01 | Dice Molecules Sv Inc | INTEGRIN INHIBITORS OF ALPHA V BETA 6 AND ALPHA V BETA 1 AND THEIR USES |
CA3218481A1 (en) | 2021-06-14 | 2022-12-22 | argenx BV | Anti-il-9 antibodies and methods of use thereof |
CA3237696A1 (en) | 2021-11-08 | 2023-05-11 | Progentos Therapeutics, Inc. | Platelet-derived growth factor receptor (pdgfr) alpha inhibitors and uses thereof |
WO2023130081A1 (en) | 2021-12-30 | 2023-07-06 | Neoimmunetech, Inc. | Method of treating a tumor with a combination of il-7 protein and vegf antagonist |
US11981694B2 (en) | 2022-01-03 | 2024-05-14 | Lilac Therapeutics, Inc. | Acyclic thiol prodrugs |
WO2023129577A1 (en) | 2022-01-03 | 2023-07-06 | Lilac Therapeutics, Inc. | Cyclic thiol prodrugs |
GB2619907A (en) | 2022-04-01 | 2023-12-27 | Kanna Health Ltd | Novel crystalline salt forms of mesembrine |
WO2024086852A1 (en) | 2022-10-21 | 2024-04-25 | Diagonal Therapeutics Inc. | Heteromeric agonistic antibodies to il-18 receptor |
WO2024102722A1 (en) | 2022-11-07 | 2024-05-16 | Neoimmunetech, Inc. | Methods of treating a tumor with an unmethylated mgmt promoter |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH02247118A (ja) * | 1989-03-17 | 1990-10-02 | Bando Chem Ind Ltd | 皮膚貼付薬シート |
JPH0457872A (ja) * | 1990-06-28 | 1992-02-25 | Bando Chem Ind Ltd | 粘着シート |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3971753A (en) * | 1973-12-13 | 1976-07-27 | Union Carbide Corporation | Polymer composites and preparation thereof |
JPH0725665B2 (ja) * | 1992-04-16 | 1995-03-22 | バンドー化学株式会社 | 皮膚貼付薬シートの製造方法 |
JPH0733646A (ja) * | 1993-07-23 | 1995-02-03 | Bando Chem Ind Ltd | 皮膚貼付薬シート |
JP3485701B2 (ja) * | 1995-11-06 | 2004-01-13 | 久光製薬株式会社 | 皮膚貼付用シート |
-
1998
- 1998-10-26 KR KR1019997005815A patent/KR100719273B1/ko not_active IP Right Cessation
- 1998-10-26 US US09/319,577 patent/US6267983B1/en not_active Expired - Lifetime
- 1998-10-26 AU AU96484/98A patent/AU730850B2/en not_active Ceased
- 1998-10-26 WO PCT/JP1998/004850 patent/WO1999021537A1/ja active IP Right Grant
- 1998-10-26 CN CNB988025140A patent/CN1152673C/zh not_active Expired - Lifetime
- 1998-10-26 DE DE69839179T patent/DE69839179T2/de not_active Expired - Lifetime
- 1998-10-26 JP JP52372899A patent/JP4395200B2/ja not_active Expired - Fee Related
- 1998-10-26 CA CA002275539A patent/CA2275539A1/en not_active Abandoned
- 1998-10-26 EP EP98950401A patent/EP0968711B9/en not_active Expired - Lifetime
- 1998-10-26 AT AT98950401T patent/ATE387192T1/de not_active IP Right Cessation
- 1998-10-28 TW TW087117832A patent/TW518228B/zh not_active IP Right Cessation
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH02247118A (ja) * | 1989-03-17 | 1990-10-02 | Bando Chem Ind Ltd | 皮膚貼付薬シート |
JPH0457872A (ja) * | 1990-06-28 | 1992-02-25 | Bando Chem Ind Ltd | 粘着シート |
Also Published As
Publication number | Publication date |
---|---|
AU730850B2 (en) | 2001-03-15 |
CN1247468A (zh) | 2000-03-15 |
WO1999021537A1 (fr) | 1999-05-06 |
KR20000069728A (ko) | 2000-11-25 |
US6267983B1 (en) | 2001-07-31 |
CN1152673C (zh) | 2004-06-09 |
EP0968711B1 (en) | 2008-02-27 |
EP0968711B9 (en) | 2008-05-28 |
JP4395200B2 (ja) | 2010-01-06 |
AU9648498A (en) | 1999-05-17 |
ATE387192T1 (de) | 2008-03-15 |
DE69839179D1 (de) | 2008-04-10 |
TW518228B (en) | 2003-01-21 |
CA2275539A1 (en) | 1999-05-06 |
EP0968711A4 (en) | 2006-06-28 |
DE69839179T2 (de) | 2009-02-19 |
EP0968711A1 (en) | 2000-01-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100719273B1 (ko) | 피부 패치 시트 및 그것을 위한 베이스 시트의 제조 방법 | |
JP2733180B2 (ja) | フレキシブル包装用ラミネート、その製造方法及びそれに用いる接着剤 | |
JP4749765B2 (ja) | 創傷保護フィルム及び医療用貼付材 | |
JP2549576B2 (ja) | 粘着シート | |
JP5196828B2 (ja) | 皮膚貼付薬シート | |
JPH0725665B2 (ja) | 皮膚貼付薬シートの製造方法 | |
JPH0635381B2 (ja) | 皮膚貼付薬シート | |
JPH0584260A (ja) | 皮膚貼付薬シート | |
JP5226230B2 (ja) | 貼付剤用粘着剤組成物及びその用途 | |
JPH0457872A (ja) | 粘着シート | |
JPH02247118A (ja) | 皮膚貼付薬シート | |
JPH01223185A (ja) | 粘着シート | |
JP3440284B2 (ja) | 皮膚貼付薬用支持体 | |
JPH0335078A (ja) | 粘着シート | |
JPH0457873A (ja) | 粘着シート | |
JP3345175B2 (ja) | 経皮投与薬用支持体 | |
JPH02166182A (ja) | 粘着シート | |
JPH01224313A (ja) | 粘着シート | |
JPH03166280A (ja) | 粘着シート | |
JPH07330589A (ja) | 経皮投与薬用支持体 | |
JPH01249719A (ja) | 皮膚貼付薬シート | |
JPH01223186A (ja) | 粘着シート | |
JPH07215844A (ja) | 皮膚貼付薬シート | |
JPS62227983A (ja) | 粘着シ−ト | |
JPH10182444A (ja) | 皮膚貼付薬シート |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
AMND | Amendment | ||
E902 | Notification of reason for refusal | ||
AMND | Amendment | ||
E601 | Decision to refuse application | ||
J201 | Request for trial against refusal decision | ||
AMND | Amendment | ||
B601 | Maintenance of original decision after re-examination before a trial | ||
J301 | Trial decision |
Free format text: TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20060126 Effective date: 20070130 |
|
S901 | Examination by remand of revocation | ||
GRNO | Decision to grant (after opposition) | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20130502 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20140418 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20150416 Year of fee payment: 9 |
|
FPAY | Annual fee payment |
Payment date: 20160419 Year of fee payment: 10 |
|
FPAY | Annual fee payment |
Payment date: 20170420 Year of fee payment: 11 |
|
LAPS | Lapse due to unpaid annual fee |